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ABSTRACT 
Various triacsin C analogs, containing different alkenyl chains and carboxylic acid 
bioisoteres including 4-aminobenzoic acid, isothiazolidine dioxide, hydroxylamine, 
hydroxytriazene, and oxadiazolidine dione, were synthesized and their inhibitions of long chain 
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fatty acyl-CoA synthetase (ACSL) were examined. Two methods, a cell-based assay of ACSL 
activity and an in situ [
14
C]-palmitate incorporation into extractable lipids were used to study the 
inhibition.  Using an in vivo leukocyte recruitment inhibition protocol, the translocation of one or 
more cell adhesion molecules from the cytoplasm to the plasma membrane on either the 
endothelium or leukocyte or both was inhibited by inhibitors 1, 9, and triacsin C.  The results 
suggest that inhibition of ACSL may attenuate the vascular inflammatory component associated 
with ischemia reperfusion injury and lead to a decrease of infarct expansion. 
 
 
Ischemia reperfusion (I/R) injury is a cascade of various cellular and molecular events, 
including impaired nitric oxide (NO) release and rapid translocation of cell adhesion molecules 
from the cytoplasmic compartment to the plasma membrane.
1
 Together, these events initiate 
leukocyte recruitment and subsequent inflammatory injury.  Long chain fatty acyl CoA 
synthetase (ACSL or LC-FACS) catalyzes the formation of a thioester between a coenzyme A 
(CoA) and a fatty acid (FA) by a two-step process as shown in equation 1.
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Protein palmitoylation occurs when the fatty acid moiety is transferred to a free SH group 
on a cysteine residue of CoA.  While fatty acyl CoA (FACoA) transferase has been described, 
the process is also thought to occur spontaneously requiring seconds to complete.
3
 Endothelial 
FA     +     ATP FA AMP
PPi
CoASH
FACoA     +     AMP (eq 1)
3 
 
nitric oxide synthase (eNOS) generates endothelial NO.  Its activity is controlled by 
palmitoylation as well as by protein-protein interaction and phosphorylation.
4
 The function of 
cell adhesion molecules necessary for neutrophil infiltration of ischemic tissue, such as p-
selectin, integrins, intercellular adhesion molecule (ICAM), and platelet endothelial cell adhesion 
molecule (PECAM), is dependent on a rapid depalmitoylaton/repalmitoylation cycle,
5-8
 
suggesting that the I/R injury cascade is dependent, at least in part, on protein palmitoylation.  
Hence, interrupting that cascade would be expected to mitigate I/R injury.  Triacsin C (Figure 1) 
blocks eNOS palmitoylation,
9
 increases post-ischemic intravascular NO generation, and inhibits 
neutrophil recruitment and infiltration in a model of ischemia.
10
 Triacsin C is a natural product 
isolated from Streptomyces aureofaciens,
11,12
 which inhibits ACSL, including those expressed by 
the vascular endothelium.
13
 Together, the data suggests that these processes are dependent on 
palmitoyl CoA formation and imply that protein palmitoylation is dependent on palmitoyl CoA 
availability. 
Our earlier work
14
 described several triacsin C analogs, including compounds 1 and 2 
(Figure 1), with high anti-viral activities.  However, the efficacy of these compounds to inhibit 
ACSL activity was not tested directly.  Here, we expand the library of triacsin C analogs, 
examine their activities as ACSL inhibitors both in vitro and in vivo, and evaluate their potential 
as inhibitors of neutrophil infiltration in an in vivo model of ischemia.  The hydroxytriazene 
function of triacsin C remains an elusive functionality to be synthesized. In the reported 
synthesis of triacsin C,
15
 the final three steps for the construction of hydroxyazoimine or 
hydroxytriazene moiety involved the hydrazone formation of (E,E,E)-2,4,7-undecatrien-1-al with 
hydrazine followed by silylation with trimethylsilyl chloride and addition to dinitrogen trioxide, 
resulting in only 0.4% yield.  The scarcity of triacsin C hinders various in vivo biological studies. 
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Moreover, the hydroxyazoimine function of triacsin C is a reactive moiety.  Hence, analogs 3 – 
12 with varying alkenyl chains, possessing different functionalities, and mimicking 
hydroxyazoimine moiety of triacsin C were synthesized and bioevaluated (Figure 1).  
 
Following the previously reported method,
14
 compounds 3 and 4 were readily synthesized 
in moderate yields from reductive amination reactions of 10-undecenal (13) and 14 and 15, 
separately, with sodium cyanoborohydride in ethanol at 25
o
C (Scheme 1).  Hydroxyamine 9 was 
obtained in 76% yield from the coupling of aldehyde 13 and hydroxylamine in ethanol followed 
by reduction with NaCNBH3. Similar treatment of aldehydes
14
 16 and 17 afforded 
hydroxyamines 10 and 18, respectively.  Addition reactions of hydroxyamine 9, 10, and 18, 
separately, with 4-(hydroxycarbonyl)phenyldiazonium chloride
16
 in methanol provided 
N
N
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N
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Figure 1. Synthesized and bioevaluated ACSL inhibitors 1 - 12 and triacsin C.
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hydroxytriazene analogs 5, 6, and 7 in 83, 48, and 42% yield, respectively.  Notably, these three 
compounds are stable molecules.  Because the imino function of 2
14
 hydrolyzes with water 
slowly, it was reduced with NaCNBH3 and HCl in methanol to furnish stable sulfonylhydrazine 
8 in a 53% yield.  Under other reaction conditions including the use of acetic acid as a catalyst in 
the reduction procedure resulted in a mixture of unidentifiable byproducts.  1,2,4-
Oxadiazolidine-3,5-dione is a carboxylic acid bioisostere,
17
 hence we synthesized compounds 11 
and 12 from 9 and 10, respectively, by the addition reactions with ethyl isocyanoformate 
followed by ring closure with NaOH.
17
  
 
Scheme 1. Synthesis of compounds 3 - 12.
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ACSL inhibition in vitro: With the exception of Compounds 2 and 8, all of the triacsin C 
analogs inhibit ACSL activity in solubilized brain endothelial bEND3 cells, and results and 
inhibitory curves are shown in Table 1 and Figure 2, respectively.  The median effective 
concentration (EC50) values ranged from ~5 µM to ~170 µM.  In contrast, triacsin C is about 10 
times more potent than compound 3, the most active analog of the series.  Compound 1 is only 
one-tenth as potent as triacsin C in the ACSL assay, yet it was at least twice as potent as triacsin 
C as an inhibitor of rotavirus replication,
14
 suggesting that the effect on rotavirus replication may 
not attribute only by the inhibition of ACSL.  Significantly, compound 3, having EC50 value of 
4.95 M and containing a 10-undecenyl chain, has similar or better inhibitory activity as the 
trienyl analog, 1 with EC50 value of 5.86 M.  Among the head groups examined, the 4-
hydroxycarbonylphenylamino moiety (in compounds 1 and 3) possesses the greatest activity.  
The carboxylic acid bioisosteres, 1,2,4-oxadiazolidine-3,5-dione derivatives 11 and 12 do not 
appear to improve the inhibitory activity.  Also, the isothiazolidine dioxides 2 and 8 are >30 
folds less active compare with compound 3.  
Table 1. Inhibition of ACSL activity in solubilized brain endothelial bEND3 cells. The EC50 
values were calculated by fitting the velocity vs. inhibitor concentration to the constrained three-
parameter log (inhibitor) vs. response function of the Prism 6.0 statistical analysis package.   
Compound EC50 (µM) Compound EC50 (µM) 
1 5.86 ± 0.54 7 26.9 ± 3.6 
2 171 ± 79.0 8 164 ± 6 0.8 
3 4.95 ± 0.74 9 70.4 ± 14.0 
4 6.88 ± 0.66 10 14.8 ± 1.6 
5 73.1 ± 9.6 11 9.04 ± 1.45 
6 74.8 ± 34.8 12 53.5 ± 33.2 
Triacsin C 0.358 ± 0.027   
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Figure 2.  Concentration effect curves of the inhibition of ACSL activity in solubilized brain 
endothelial bEND3 cells for each of the analogs, as compared to Triacsin C. 
 
 
 
ACSL inhibition in situ:  Compounds 1, 2, 3, 4, 7, and 9 were compared to triacsin C as 
inhibitors of [
14
C]-palmitate incorporation into extractable lipids of bEND 3 cells, and results are 
shown in Figure 3A.  Each of the analogs, with the exception of compound 2, showed significant 
inhibition of ACSL, with a potency ratio of triacsin C > 3 > 1 > 4 > 9 = 7 > 2 and mirroring that 
of in vitro ACSL inhibition.  [
14
C]-Palmitoylated lipids were also measured in aqueous fraction 
(Figure 3B) and media (Figure 3C), and the total recovered radioactivity (lipid + aqueous + 
media) was calculated (Figure 3D).  The control cultures incorporated 40.2 ± 2.6 fmoles [
14
C]-
palmitate/µg of lipid.  Incorporation of radioactive fatty acids into lipid is a two-step process.  
First, the FACoA derivative is formed, a reaction mediated by ACSL and second, the fatty acid 
moiety is transferred to an available site during de novo lipid synthesis or during remodeling of 
existing lipids.  These reactions are mediated by various acyl transferases, so that simply 
demonstrating that the lesser radioactivity in the lipid fraction is insufficient to distinguish 
between inhibition of ACSL and the relevant acyl transferase.   
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Free palmitic acid is insoluble in aqueous systems at neutral pH, while the palmitoyl CoA 
derivative has appreciable water solubility (about 1.74 g/L).  Thus, free palmitic acid is more 
likely to partition into the CHCl3 layer of the lipid extraction, while the CoA derivative is more 
likely to remain in the aqueous layer.  As shown in Figure 3B, there was significantly less 
radioactivity in the aqueous layer for each of the compounds, with the exception of compound 2.  
Furthermore, the potency ratio for inhibition of radioactivity in the aqueous layer is similar to 
that for inhibition of incorporation into extractable lipids.  Together, these data are consistent 
with the inhibition of ACSL and not with inhibition of an acyl transferase.  Alternative 
explanations might include reduced total lipid mass, or loss of radioactivity to oxidation.  The 
mass of lipids recovered was slightly greater than control for all compounds tested, with the 
exception of compound 2.  In cells treated with triacsin C or compounds 1, 3, 4, 7 and 9, the 
mean lipid extracted did not differ with treatment, and was 127 ± 6% of control.  The 
unincorporated radioactivity in the media (with the exception of compound 2) was greater in 
treated cells as compared to control cells, as shown in Figure 3C.  Finally, the total recovery of 
radioactive material (media + lipid + aqueous) did not differ among the compounds tested, and 
was not different from control (Figure 3D).  The uniform recovery of radioactivity in both the 
control and treated cells strongly suggests that treatment did not increase -oxidation.  Thus, the 
reduced incorporation into lipids is not likely to be the consequence of reduced overall lipid 
content or increased  oxidation of fatty acid.  The possible remaining interpretation of the data 
is that the reduced incorporation of [
14
C]-palmitate into extractable lipids is the consequence of 
inhibition of ACSL. 
 
Figure 3.  In situ inhibitions of ACSL by triacsin C and analogs in bEND3 brain endothelial 
cells, as evaluated by the incorporation of [
14
C]-palmitic acid into extractable lipid (A), aqueous 
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(B), media (C), and recovery (D).  Triacsin C was used at 1.5 µM, while all other compounds 
were evaluated at 15 µM.  Differences between the treatment groups and control were evaluated 
by one-way ANOVA, followed by Dunnett’s t test for significance.  * = p<0.05; ** = p < 0.01; 
*** = p < 0.001; ****; = p < 0.0001.  n = 3 to 9 independent experiments. 
 
Inhibition of leukocyte recruitment: Previously, we demonstrated that 5µM triacsin C 
virtually abolished neutrophil recruitment in a model of ischemia.
10
 Figure 4 compares the 
effects of compounds 1 and 9 (as representative analogs) to that of triacsin C.  Both compounds 1 
and 9 significantly inhibited rolling, adhesion, and extravasation.  The magnitudes of inhibition 
for both compounds were less than that of 5 µM triacsin C, but mirrored the potencies of 
compounds 1 and 9 to inhibit ACSL activity.  Triacsin C inhibits palmitoylation of multiple 
proteins including eNOS.
9
 This suggests that inhibitors of ACSL exert their effects, at least in 
part, by inhibiting protein palmitoylation, consequently changing their function and/or sub-
cellular location.  Protein palmitoylation is a very rapid (half-time of seconds) common pathway 
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facilitating protein trafficking.
3,18
 Indeed, proteins that are rapidly re-partitioned between 
cytoplasm and membrane are suspects for palmitoylation.
3
 Cell adhesion proteins such as 
PECAM
5
 and P-selectin
6
 require palmitoylation for translocation to the plasma membrane early 
in the ischemic injury cascade.  Our observation that triacsin C and both compounds 1 and 9 
inhibit leukocyte recruitment strongly suggest that all three compounds inhibit translocation of 
one or more cell adhesion molecules from the cytoplasm to the plasma membrane on either the 
endothelium or leukocyte or both.  Furthermore, the potency ratio of these three compounds to 
inhibit leukocyte recruitment is the same as the potency ratio for inhibition of ACSL activity.  
Taken together, the data strongly suggest that inhibiting ACSL may attenuate the vascular 
inflammatory component associated with I/R injury,
1
 consequently limiting infarct expansion.  
 
Figure 4.  The L-NAME induced leukocyte recruitment at 120 minutes in the presence of 
compounds 1 and 9.  Rolling, adhesion and extravasation were measured in post-capillary 
venules of the mesentery, a model of ischemia, and in the presence or absence of 5 or 50 µM 
compound 1 or 50 µM compound 9.  The rolling, adhesion and extravasation rates for 50 µM 
compound 1 and 5 µM triacsin C were not different from each other nor were they different from 
vehicle alone.  When evaluated at 5 µM, compound 1 inhibited the recruitment to about half the 
extent as at 50 µm.  Compound 9 at 50 µM was about as effective as compound 1 at 5 µM.  Each 
bar represents the mean ± SEM of 3 to 7 independent experiments.  
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In conclusion, various triacsin C analogs were synthesized and their ACSL inhibitory 
activities and amelioration of the vascular inflammatory component associated with 
ischemia/reperfusion were studied.  4-Akenylaminobenzoic acid 1 and 3 showed the greatest 
activities.  Further optimization of this class of ACSL inhibitors is possible, which may lead to 
the understanding of the consequence of ACSL inhibition effect in ischemia and treatment of 
ischemia. 
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